1107 related articles for article (PubMed ID: 11707813)
21. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
[TBL] [Abstract][Full Text] [Related]
22. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
23. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
24. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
Brunvand MW; Bensinger WI; Soll E; Weaver CH; Rowley SD; Appelbaum FR; Lilleby K; Clift RA; Gooley TA; Press OW; Fefer A; Storb R; Sanders JE; Martin PL; Chauncey T; Maziarz RT; Zuckerman N; Montgomery P; Dorn R; Weiden PL; Demirer T; Holmberg LA; Schiffman K; McSweeney PA; Buckner CD
Bone Marrow Transplant; 1996 Jul; 18(1):131-41. PubMed ID: 8832006
[TBL] [Abstract][Full Text] [Related]
25. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
Weaver CH; Petersen FB; Appelbaum FR; Bensinger WI; Press O; Martin P; Sandmaier B; Deeg HJ; Hansen JA; Brunvand M
J Clin Oncol; 1994 Dec; 12(12):2559-66. PubMed ID: 7989929
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
27. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.
Cao TM; Horning S; Negrin RS; Hu WW; Johnston LJ; Taylor TL; Shizuru JA; Hoppe RT; Brown BW; Blume KG; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2001; 7(5):294-301. PubMed ID: 11400952
[TBL] [Abstract][Full Text] [Related]
28. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
29. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
31. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
[TBL] [Abstract][Full Text] [Related]
32. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant.
Arranz R; Tomás JF; Gil-Fernández JJ; Martínez-Chamorro C; Granados E; Alegre A; Figuera A; Vázquez L; Cámara R; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Apr; 21(8):779-86. PubMed ID: 9603401
[TBL] [Abstract][Full Text] [Related]
33. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
34. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
35. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
[TBL] [Abstract][Full Text] [Related]
36. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.
Gulati S; Yahalom J; Acaba L; Reich L; Motzer R; Crown J; Toia M; Igarashi T; Lemoli R; Hanninen E
J Clin Oncol; 1992 Jun; 10(6):936-41. PubMed ID: 1588372
[TBL] [Abstract][Full Text] [Related]
37. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.
Sweetenham JW; Pearce R; Taghipour G; Blaise D; Gisselbrecht C; Goldstone AH
J Clin Oncol; 1996 Sep; 14(9):2465-72. PubMed ID: 8823324
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
Bertz H; Zeiser R; Lange W; Fetscher S; Waller CF; Finke J
Ann Oncol; 2004 Sep; 15(9):1419-24. PubMed ID: 15319249
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]